1	Data-driven methodology for discovery and response to pulmonary
2	symptomology in hypertension through AI and machine learning: Application
3	to COVID-19 related pharmacovigilance
4	
5	
6	Xuan Xu ^{1,2,3} , Jessica Kawakami ^{1,4,5} , Nuwan Indika Millagaha Gedara ^{1,3,6} , Jim Riviere ^{1,7} , Emma
7	Meyer ^{1,4} , Gerald J. Wyckoff ^{1,4,5} , and Majid Jaberi-Douraki ^{1,2,3} , *
8	¹ 1DATA Consortium, <u>www.1DATA.life</u> , USA
9	² Department of Mathematics, Kansas State University
10	³ Kansas State University Olathe, Olathe, KS 66061-1304
11	⁴ School of Pharmacy, Division of Pharmacology and Pharmaceutical Sciences, University of
12	Missouri-Kansas City
13	⁵ Molecular Biology and Biochemistry, School of Biological and Chemical Sciences, University of
14	Missouri-Kansas City
15	⁶ Department of Business Economics, University of Colombo, Sri Lanka
16	⁷ Kansas State University and North Carolina State University
17	
18	
19	*Correspondence: Majid Jaberi-Douraki, jaberi@ksu.edu
20	
21	
22	Running title: AI and machine learning data-driven methods: COVID19 related
23	pharmacovigilance

24 ABSTRACT

Background: Potential therapy and confounding factors including typical co-administered medications, patient's disease states, disease prevalence, patient demographics, medical histories, and reasons for prescribing a drug often are incomplete, conflicting, missing, or uncharacterized in spontaneous adverse drug event (ADE) reporting systems. These missing or incomplete features can affect and limit the application of quantitative methods in pharmacovigilance for metaanalyses of data during randomized clinical trials.

31 Methods: In this study, we implemented adaptive signal detection approaches to correct spurious 32 association, hidden factors, and confounder misclassification when the covariates are unknown or 33 unmeasured on medications affecting the renin-angiotensin system (RAS), potentially creating an 34 increased risk of life-threatening outcomes in high-risk patients.

35 **Results:** Following multiple filtering stages to exclude insignificant and noise-driven reports, we 36 found that drugs from antihypertensives agents, urologicals, and antithrombotic agents (macitentan, 37 bosentan, epoprostenol, selexipag, sildenafil, tadalafil, and beraprost) form a similar class with a 38 significantly higher incidence of pADEs. Macitentan and bosentan were associates with 64% and 39 56% of pADEs, respectively. Because these two medications are prescribed in diseases affecting 40 pulmonary function and may be likely to emerge among the highest reported pADEs, in fact, they 41 serve to validate the methods utilized here. Conversely, doxazosin and rilmenidine were found to 42 have the least pADEs in selected drugs from hypertension patients. Nifedipine and candesartan 43 were also found by our signal detection methods to form a drug cluster, shown by several studies 44 an effective combination of these drugs on lowering blood pressure and appeared an improved 45 side effect profile in comparison with single-agent monotherapy.

46 **Conclusions:** We consider pulmonary ADE (pADE) profiles in a long-standing group of 47 therapeutics, RAS-acting agents, in patients with hypertension associated with high-risk for 48 COVID-19. Using these techniques, we confirmed our hypothesis that drugs from the same drug 49 class could have very different pADE profiles affecting outcomes in acute respiratory illness. We 50 found that several indidvual drugs have significant differences between their drug classes and 51 compared to other drug classes.

Funding: GJW and MJD accepted funding from BioNexus KC for funding on this project but
BioNexus KC had no direct role in this article.

54 Clinical trial number: N/A

55

56 Author Summary

57 Underlying comorbidities continue to negatively affect COVID-19 patients. A recent focus has 58 been on medications affecting RAS. Therefore, with the advent of COVID-19 acute respiratory 59 distress syndrome (ARDS) in high-risk patients with hypertension, identifying specific RAS 60 medications with the lowest incidence of pADEs would be beneficial. For this purpose, we curated 61 the FDA ADE database to search for information related to human pADEs. As part of post-62 marketing drug safety surveillance, state/federal regulatory agencies and other institutions provide massive collections of ADE reports, these large data-sets present an opportunity to investigate 63 64 ADEs to provide patient management based on comparative population data analysis. The 65 abundance and prevalence of ADEs are not always detectable during randomized clinical trials 66 and before a drug receives FDA approval for use in the clinic, which may appear with more 67 widespread use. This is especially true for specific agents or diseases since there are simply too

- 68 few events to be assessed, even in a large clinical trial for side effect profiles of specific disease
- 69 states. For this purpose, we employed a novel method identifying extraneous causes of differential
- 70 reporting including sampling variance and selection biases by reducing the effect of covariates.

72 INTRODUCTION

73 The coronavirus disease 2019 (COVID-19) pandemic continues with 115,094,614 confirmed cases 74 and over 2.6 million deaths as of March 5, 2021 (1, 2). Surprisingly, it is estimated that as high as 75 45% of infected individuals may remain asymptomatic, contributing to disease transmission and 76 underlying the disparity in symptomology (3). A commonality of severe clinical course and 77 mortality is comorbid conditions such as diabetes, heart disease, obesity, and hypertension (4). Hypertension was recognized early on as being a prevalent risk factor (5), possibly due to its 78 79 pervasiveness. Hypertension affects 23% of adults in China, where the original study was 80 conducted, but affects 45% of US adults. Moreover, specific antihypertensive medications, namely 81 angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs), 82 target proteins of the renin-angiotensin system (RAS) (6). The RAS is intricately linked to initial 83 infection and possibly the progression of COVID-19 through a RAS receptor, angiotensin-84 converting enzyme 2 (ACE2), which acts as the viral entry point of coronavirus SARS-CoV-2 (7, 85 8).

86

87 In recent years, data science has emerged as a new and important discipline in medicine and 88 healthcare. Different quantitative therapeutic efforts in drug repurposing or repositioning combined 89 with adverse drug event (ADE) identification have led to more efficient therapies while improving 90 the clinical course, lowering fatality, and decreasing cost burden (9). Our previous work focused 91 on the incidence of pulmonary ADEs associated with ACEI and ARB use in patients with 92 hypertension and other comorbidities (10, 11). Our findings indicate that specific drugs—rather 93 than entire classes—have higher incidences of pulmonary ADEs, which may have implications for 94 treating patients diagnosed with COVID-19. Most epidemiological studies are not this granular as 5

95 they do not analyze drug effects at the individual drug level but rather compare pharmacological 96 classes. The current study examines additional drugs that more broadly target hypertension, 97 including pulmonary hypertension, to describe methods used to identify clinically important 98 patterns of ADE data. We utilized the Anatomical Therapeutic Chemical (ATC) classification 99 system from the World Health Organization (WHO) Collaborating Center for Drug Statistics 100 Methodology (https://www.whocc.no/). The ATC system classifies drugs based on site of action 101 in addition to chemical, pharmacological, and therapeutic properties (12). Here we identify a clear 102 signal distinct from different drugs in patients with hypertension as an underlying medical 103 condition which helps to quantify the anomaly and unexpectedness of an ADE reported for a drug through disproportionality analysis. For this purpose, we proceeded with a specific pairwise 104 105 analysis of individual drugs compared to the drug classes using a modified empirical 106 Bayes method to identify any distinctions between drugs within a class and compared to other 107 classes.

108

109 In our previous work, thirteen different pulmonary ADEs were selected based on clinical 110 importance, and as they were prevalent among the top reported symptoms in patients with COVID-111 19, to assess the related variation due to adverse event differences (10, 11). In the present work, 112 we include 25 pulmonary, infectious disease, or cardiac-associated ADEs. Our novel method 113 identifies extraneous causes of differential reporting including sampling variance and selection 114 biases by reducing the effect of covariates. This method is both adaptive (it removes different 115 covariates for different drugs) and appropriate for the systematic application and routine analysis 116 (13). We hypothesize that drugs from the same class based on the Anatomical Therapeutic 117 Chemical (ATC) classification system could have different ADE profiles. For this purpose,

118 penalized regression method will be used to detect clusters of drugs, may differ from the ATC 119 classification, and will be validated by the Friedman test (14-16). Safety signals for a specific drug 120 and associated adverse events are then identified and evaluated through different methods, such 121 as the proportional reporting ratio (PRR) (14), the relative reporting ratio (RR) (17), the 122 information component (IC) (18), and the empirical Bayes geometric mean (EBGM) 123 (17). These methods are utilized to calculate the ratio of an ADE compared to the same event 124 occurring with other drugs, however, PRR or RR is more liberal when an event incidence is small 125 (19).

126

127 **RESULTS**

128 **Preprocessing and Data Cleaning**

129 Here we briefly explain the data preprocessing and cleansing that will be used in different 130 subsections. The focus of each subsection is given by the amount of data that will be used. A total 131 of 480.236 spontaneous ADE reports for patients with hypertension were retrieved from our 132 1DATA databank of the FAERS database from the first quarter of 2004 until the first quarter of 2020. Alternatively, ADEs can be categorized by drug for a total of 612,733 reports (Table 1) 133 134 arising from patients taking more than one drug. For example, a single ADE reported for a patient 135 taking 2 different drugs, will generate one ADE report for each drug. This hypertension dataset 136 was aggregated to 1520 ADEs in HLT codes corresponding to 1131 drugs with unique active 137 substances. Next, drugs were excluded when the number of ADEs due to the fact that each drug 138 was reported less than 500 times, accounting for approximately less than 0.1% of the data. 139 Furthermore, 98.8% of the data corresponded to 134 of the 1131 drugs (**Table 1** with the column

header: # Drugs after initial filtering; this dataset will be exploited to calculate the relative risk for
the disproportionality measures of a drug-ADE occurrence). This study focused on the 98.8% of
the data remaining after the elimination of insignificant and noise-driven reports. The 134 drugs
were grouped according to the following ATC drug classes (Table 1): ACEIs, ARBs, other RAS
agents, other Antihypertensives Agents (AHAs), Antithrombotic Agents (ATAs), Beta blocking
Agents (BBAs), Calcium channel blockers (CCBs), Diuretics, Lipid modifying agents, Urologicals
(UAs), Vasoprotectives, and Combinations of antihypertensives (COMBs).

147 Since there were 5 unrelated pulmonary ADEs in the database (coronavirus infections, conditions 148 associated with abnormal gas exchange, neonatal hypoxic conditions, newborn respiratory 149 disorders NEC, pulmonary hypertensions), the hypertension dataset was further reduced to reports 150 corresponding to the following 30 pulmonary ADEs: bacterial lower respiratory tract infections, 151 breathing abnormalities, bronchial conditions NEC, bronchospasm and obstruction, congenital 152 lower respiratory tract disorders, coughing and associated symptoms, fungal lower respiratory 153 tract infections, infectious disorders carrier, lower respiratory tract infections NEC, lower 154 respiratory tract inflammatory and immunologic conditions, lower respiratory tract neoplasms, 155 lower respiratory tract radiation disorders, lower respiratory tract signs and symptoms, 156 occupational parenchymal lung disorders, parasitic lower respiratory tract infections, 157 parenchymal lung disorders NEC, pleural conditions NEC, pleural infections and inflammations, 158 pleural neoplasms, pneumothorax and pleural effusions NEC, pulmonary oedemas, pulmonary 159 thrombotic and embolic conditions, respiratory failures (excl neonatal), respiratory signs and 160 symptoms NEC, respiratory syncytial viral infections, respiratory tract disorders NEC, respiratory 161 tract infections NEC, respiratory tract neoplasms NEC, vascular pulmonary disorders NEC, and 162 viral lower respiratory tract infections. Of the 30 pulmonary ADEs, 5 ADEs were additionally

excluded from the analysis since we did not have any reports for these ADEs: *congenital lower respiratory tract disorders, lower respiratory tract radiation disorders, parasitic lower respiratory tract infections, respiratory tract neoplasms NEC, and viral lower respiratory tract infections.*

167

168 Relative Risk (RR)

169 One of the frequentist methods, the relative reporting ratio (RR), based on the disproportionality 170 measures of a drug-ADE occurrence compared to other drug-event combinations was applied to 171 evaluate the weighting of drugs. To start our first analysis, we constructed a large contingency 172 table for the entire data from 134 selected drugs based on their frequencies with respect to all 1520 173 reported ADEs in HLT codes from MedDRA. We imposed the assumption that an ADE is selected 174 when RR > 2 for a specific drug to assess the drug disproportionality in pharmacovigilance data by 175 observed-expected ratios prior to the EBGM analysis, a more conservative and accurate way of 176 disproportionality evaluation. Taking into account only 25 pulmonary ADEs in HLT codes, we 177 then obtain the results of **Table 2** displaying the top 22 drugs with their corresponding number of 178 pulmonary ADEs when RR > 2. The order from the number of pulmonary ADEs is arranged based 179 on the EBGM results after GLASSO elimination and the clustering given in **Table 1** that will be 180 explained below. RR is also utilized to calculate the baseline frequency for EBGM and to construct 181 the PCA as explained below.

183 Principle Component Analysis (PCA)

184 RR calculated for the expected frequency of 25 pulmonary ADEs associated with 134 drugs 185 prescribed to patients with hypertension was used to generate the matrix for the PCA plot. This 186 helped illustrate how the loadings of pulmonary features could separate drugs in a 2D or 3D space. 187 Fig 1A shows 134 drugs in a 2D PCA panel following a V shape scatter plot, no clear separation 188 can be intuitively observed. ADEs (blue text) are also superimposed on the graph to obtain the 189 corresponding loadings, direction, and weights with regards to the drugs. Generally, two clusters 190 of pulmonary issues, one in the direction of the X-axis, and another in the Y-axis played an 191 important role in separating these drugs in the space of PC1 and PC2. Twelve different pulmonary 192 ADEs in HLTS codes (breathing abnormalities, bronchospasm and obstruction, coughing and 193 associated symptoms, lower respiratory tract infections NEC, lower respiratory tract inflammatory 194 and immunologic conditions, lower respiratory tract signs and symptoms, parenchymal lung 195 disorders NEC, pneumothorax, and pleural effusions NEC, pulmonary oedemas, pulmonary 196 thrombotic and embolic conditions, respiratory failures (excl neonatal), and respiratory tract 197 disorders NEC) exhibited similar impact by differentiating these drugs when projected to PC1 (X-198 axis), and seven pulmonary ADEs in HLTS codes (bronchial conditions NEC, fungal lower 199 respiratory tract infections, pleural conditions NEC, pleural infections and inflammations, 200 respiratory signs and symptoms NEC, respiratory syncytial viral infections, and vascular 201 pulmonary disorders NEC) contributed the most when projected to PC2 (Y-axis). A detailed 202 contribution of all pulmonary variables is given in **Table S1** in **Supporting Information** and will 203 be reviewed in the discussion.

205 Fig 1B illustrates how the pulmonary ADEs are separated in a 3D space. The first, second, and 206 third principal components, PC1, PC2, and PC3, explain more than 90% of the variation. Drugs 207 from different branches in the 3D plot represent distinctive effects of pulmonary ADEs on the 208 separation. This figure shows the optimal representation of three active variables in biplots 209 acquired by PCA by diminishing the effect of supplementary variables that have no or little 210 influence on the pulmonary ADEs. Consistent with our previous finding (11), Quinapril and 211 Trandolapril in hypertensive patients have a notably higher incidence of pulmonary ADEs 212 compared with its drug class as well as other classes, Fig 1B.



Fig 1. Principal component analysis of the expected count for 134 drugs (from 12 ATC drug classes) in 2D (A) and 3D (B) spaces using the log expected value of RR, log *E*. In Panel B, individual drugs are (significantly) separated on the extreme edges are marked by (1) amlodipine, (2) quinapril, (3) trandolapril, (4) nilvadipine, (5) azosemide, (6) azelnidipine, and (7) treprostinil. An interactive figure can be found on the 1DATA home page. Click the following URL to see the figure: https://ldata.life/pages/publication/figure1B.html.

214

215 Empirical Bayesian Geometric Mean (EBGM)

216 While the RR method is widely utilized due to its simplicity and user-friendly processing, it is 217 difficult to dismiss high variability for infrequent occurrences. The assessment of drugs or ADEs 218 based on RR is variable because of information that the RR methodology does not include, 219 including underreported or overreported events. To assess the effect that the RR methodology has 220 when a small number of ADE occurrences are compared to the whole database, the 5th percentiles 221 from the lower confidence interval of EBGM (EB05) were used as a very conservative alternative, 222 and the results are compared to RR. This assessment was performed using EBGM, is reported 223 similar to the prevalence evaluation using RR values from above. The frequencies of a single drug 224 having multiple ADEs in HLT groups or a single HLT ADE occurrence in multiple drugs were 225 calculated. We then found that the top ten drugs with pulmonary ADEs consisted of AHAs, ATAs, 226 and UAs. Bosentan, tadalafil, treprostinil, and beraprost based on EBGM were ranked substantially 227 higher than their corresponding ranks when using RR, with respect to pulmonary ADEs. This suggests that the conservative, EBGM method with a 5th percentile cut-off will allow for the 228 229 examination of large datasets of ADEs when high variability is present in the number of ADEs

across drugs or drug classes, and still allow for a robust reporting methodology as compared to the
RR methodology. This allows analysis of very large sets of drugs and ADEs (such as
approximately 500,000x134 matrix here) without loss of sensitivity or imparting an over-emphasis
on ADEs from infrequently prescribed drugs.

234

235 GLASSO

236 The total number of distinct drugs used by patients with hypertension was 134 after filtering out 237 drugs with very low frequency (<0.001) in the PCA section. EBGM data were used to construct 238 the new feature matrix for different drug classes. Then 44 drugs were selected based on two 239 conditions: (1) the lower confidence interval of EBGM, EB05, of drugs was larger than one, and 240 (2) a minimum of two different pulmonary ADEs is associated with each drug, **Table 1**. We found 241 that few drugs in ACEIs, diuretics, and combinations tended to cause pulmonary issues. More than 242 half of the drugs were in ARBs, AHAs, ATAs, and CCBs when considering two different 243 pulmonary ADEs in the HLT level. After two filtering steps, 44 drugs were set as the input for the 244 penalized regression GLASSO. To have an adequate number of correlated drugs, the tuning 245 parameter λ of GLASSO was adjusted to shrink the less associated drugs to 0, which accounted for 50% of the selected drugs. The remaining 22 drugs selected by the GLASSO method based on 246 247 Pearson correlation were classified using the therapeutic group Cardiovascular System (C01: 248 Cardiac Therapy, C02: Antihypertensives, C03: Diuretics, C04: Peripheral Vasodilators, C05: 249 Vasoprotectives, C07: Beta Blocking Agents, C08: Calcium Channel Blockers, and C10: Lipid 250 Modifying Agents), except for agents acting on RAS, which are the pharmacological subgroup 251 C09 (C09A: ACE Inhibitors, C09B: Ace Inhibitors, Combinations, C09C: Angiotensin II Receptor

Blockers (ARBS), and C09X: Other Agents Acting On the Renin-Angiotensin System,), the third
level was applied to classify the RAS drugs since RAS drugs are the frontline agents in
hypertension, Table 1.

255

Table 1. Drug class after applying first the two filtering rules to obtain 44 drugs and then the

	# Donorta	# Drugs after	# Drugs correspond to ≥ 2	Drugs using	
Drug class	# Reports	initial filtering	ADEs in HLT codes when		
	(10tal 012,755)	(Total 134)	EB05>1 (Total 44)	GLASSO (10tal 22)	
ACEIs	69,327	13	3	1	
ARBs	87,415	8	5	3	
Other RAS agents	3,471	1	0	0	
Other Antihypertensive	120,425	14	7	4	
Antithrombotic Agents	67,767	10	7	3	
Beta Blocking Agents	74,574	13	3	1	
Calcium Channel Blockers	86,399	18	10	6	
Diuretics	29,394	14	3	1	
Lipid Modifying Agents	2,634	4	0	0	
Urologicals	18,186	4	2	2	
Vasoprotectives	909	1	0	0	
Combinations	52,232	34	4	1	

elimination process from the penalized regression GLASSO to obtain 22 drugs.

258

259 Circos plot

The drug-drug correlation matrix with shrinkage is displayed in a circular layout, depicting drug class and associations between drugs from different classes (**Fig 2**). For drugs in ACEIs, ARBs, AHAs, and BBAs, no association was observed between drugs within the same class. More withinclass associations were depicted in AHAs, CCBs, and combinations. **Fig 2A** shows the association between the remaining 22 drugs after then the elimination process from the penalized regression GLASSO. After these stringent filtering methods, drug classes exhibit very low significant

266 correlations between drugs from the same class. This result is observed in **Fig 2A** by very few
267 associations between drugs in the same class. Therefore, drug clustering using the RCM reordering
268 method was employed in **Fig 2A**, with bridges connecting associated drugs. Without a doubt, this
269 analysis corroborates our hypothesis that drugs from the same ATC class may have different
270 pulmonary ADE profiles.

271

Given the 22 drugs selected by GLASSO, **Table 2** shows the assessment of drugs exclusively with respect to their pulmonary events. In the second column, # pulmonary ADEs defines the number of drug-ADE pairs from EBGM, which are depicted in the following section. Similarly, # pulmonary ADEs in the fourth column denotes the results when RR is larger than two. The order



Figure 2. Two layouts of Circos plot for 22 hypertensive drugs selected by GLASSO. Circos plots of drugs were obtained based on the EBGM matrix after applying GLASSO. Edge bundling linkages for better visualization and drugs were selected by GLASSO with edge bundling. Grouped drugs based on their classes were assigned the same color based on their classes (A). Applying RCM reordering and edge bundling for grouping drugs based on the ATC class and edge bundling (B).

276 of drugs listed in **Table 2** is calculated based on the original 44 drugs from the EBGM scores and 277 here we only show the arrangement for the remaining 22 drugs out of 44 drugs. Beraprost showed 278 13 pulmonary ADE profiles reported more commonly than other drugs used for patients with 279 hypertension based on the estimated RR. Macitentan and Selexipag were equally located in the 280 second most commonly reported drugs, each of which with 10 pulmonary ADEs. In contrast, 281 beraprost was corrected from being the top drug with most pulmonary issues and then ranked down 282 to the tenth location by EBGM. The assessment for bosentan and tadalafil also changed radically 283 when the comparative analysis was done using RR or EBGM.

Table 2. The number of pulmonary ADEs when RR larger than two or the 5th quantile of EBGM,

286	EB05, large than t	wo after GLASSO	filtering process	implemented in	Table 1
-----	--------------------	-----------------	-------------------	----------------	---------

Drug	# pulmonary ADEs	Order by EBGM	# pulmonary ADEs	Order by RR
Macitentan	16	1	10	2
Bosentan	14	2	5	11
Epoprostenol	11	4	9	4
Selexipag	10	5	10	2
Sildenafil	10	6	7	6
Tadalafil	10	7	3	44
Beraprost	7	10	13	1
Nifedipine	5	13	5	11
Candesartan	4	16	3	34
Althiazide\Spironolactone	3	20	4	18
Bisoprolol	3	21	#N/A	#N/A
Imidapril	3	24	5	11
Azelnidipine	2	30	4	23
Azilsartan Kamedoxomil	2	31	3	32
Bendroflumethiazide	2	32	3	33
Benidipine	2	33	5	11
Cilnidipine	2	34	5	11
Doxazosin	2	36	3	36
Lercanidipine	2	39	1	90
Nicardipine	2	40	5	11
Rilmenidine	2	42	#N/A	#N/A
Telmisartan	2	43	4	30

288	From GLASSO and Table 2 , we can now obtain the ADE profiles in HLT groups for each drug in
289	the newly identified group class, which we called GLASSO (GL) Clusters. The ADEs together
290	with the drug classes from ATC and GL Clusters based on EB05>1 are arranged in Table 3 and
291	depicted by an arc diagram in Fig S3, Supporting Information. It is apparent from Fig 2 and
292	Table 3 that GL Cluster 1 consists of most associated drugs with most pulmonary ADEs assessed
293	by EBGM.

- 294
- 295 **Table 3.** Comparative analysis of each drug and associated pulmonary ADEs based on our new

296 classification from different GLASSO (GL) Clusters

Drug	Drug Class	ADEs for EB05>1 (n) *	GL Cluster	
Macitentan	AHAs	1-15,17 (16)	1	
Bosentan	AHAs	1,2,4-15 (14)	1	
Epoprostenol	ATAs	1,2,4-9,11,12,15 (11)	1	
Selexipag	ATAs	2,4-12 (10)	1	
Sildenafil	UAs	1,2,4-12 (10)	1	
Tadalafil	UAs	1,2,4-12 (10)	1	
Beraprost	ATAs	1,2,5-9 (7)	1	
Nifedipine	CCBs	1-3,15,16 (5)	2	
Candesartan	ARBs	1,3,14,16 (4)	2	
Althiazide\Spironolactone	COMBs	4,10,11 (3)	3	
Rilmenidine	AHAs	4,10 (2)	3	
Bisoprolol	BBAs	1,2,14 (3)	4	
Lercanidipine	CCBs	1,14 (2)	4	
Imidapril	ACEs	1-3 (3)	5	
Azelnidipine	CCBs	1,3 (2)	5	
Azilsartan Kamedoxomil	ARBs	1,3 (2)	5	
Benidipine	CCBs	1,2 (2)	5	
Cilnidipine	CCBs	1,2 (2)	5	
Telmisartan	ARBs	1,3 (2)	5	
Bendroflumethiazide	TDAs	3,13 (2)	6	
Doxazosin	AHAs	3,13 (2)	6	
Nicardipine	CCBs	3,13 (2)	6	
* Below we have ADEs found for each dru	ıg:	9. Vascular Pulmonary Disorders NEC		
1. Parenchymal Lung Disorders NEC		10. Bronchospasm and Obstruction		
2. Pneumothorax and Pleural Effusions NE	C	11. Coughing and Associated Symptoms		
3. Lower Respiratory Tract Inflammatory a	and	12. Respiratory Syncytial Viral Infections		
Immunologic Conditions		13. Bronchial Conditions NEC		
4. Respiratory Tract Disorders NEC		14. Pulmonary Thrombotic and Embolic Conditions		
5. Breathing Abnormalities		15. Lower Respiratory Tract Infections NEC		
6. Lower Respiratory Tract Signs and Sym	ptoms	16. Fungal Lower Respiratory Tract Infections		
7. Pulmonary Oedemas		17. Pleural Infections and Inflammations		
8. Respiratory Failures (Excl Neonatal)				

297 Friedman test and multiple pairwise comparisons

298 To test the significant difference between drugs grouped by the original ATC classes and the GL 299 Clusters, which were from a shrinkage correlation matrix, a non-parametric Friedman test was 300 applied to compare separately the magnitude of difference when drugs in the same group for the 301 ATC classes or the GL Clusters. Table 4 summarizes the results of the p-value for different 302 comparative analyses in the ATC classes or the GL Clusters. A p-value of 0.199 indicates that no 303 differences in EBGM of pulmonary ADEs for different drugs in GL Cluster 1 when excluding 304 Tadalafil. Similarly, GL Clusters 2, 3, 4, 5, and 6 showed no significant differences in EBGM 305 respectively (**Table 4**). However, given the original ATC class drugs belonging to, the Friedman 306 test did show significant differences in six of the ATC class before GLASSO. The same test was 307 applied to 22 drugs selected from GLASSO, only drugs in UAs showed no significant differences 308 in EBGM of pulmonary ADEs. This shows that instead of grouping drugs from the same ATC 309 class, isolated groups from GLASSO showed homogeneity.

310

	311	Table 4.	The Friedman	test for drugs	in ATC	class and	GLASSO	class.
--	-----	----------	--------------	----------------	--------	-----------	---------------	--------

ATC Class	p-value (44 drugs)	p-value (22 drugs)
ACEIs	0.271	-
ARBs	< 0.001	< 0.001
AHAs	< 0.001	< 0.001
ATAs	< 0.001	< 0.001
BBAs	0.0232	-
CCBs	0.001	0.001
COMBs	0.236	-
TDAs	0.0329	-
UAs	0.127	0.127

luster	The p-value for 22 drugs
1	< 0.001 (0.199, when
	excluding Tadalafil)
	0.110
	0.884
	0.346
	0.127
	0.0522
	luster

<sup>Pairwise drug class comparisons based on ATC class are shown for all the pairs (nine drug classes:
ACEIs, ARBs, AHAs, ATAs, BBAs, CCBs, COMBs, TDAs, and UAs) in Table S5-A in</sup>

315 **Supporting Information**. The EBGM scores from the pulmonary ADE profiles were statistically 316 significant for the nine ATC classes using the Friedman test (*p*-value = 0.0072, Fig 3). Pairwise 317 comparisons showed no significant differences among any two ATC classes from the adjusted p-318 value (Table S5-A in Supporting Information). However, using drug class determined by 319 GLASSO, Wilcoxon signed-rank test between groups revealed significant differences in EBGM 320 of pulmonary ADEs between GL Cluster 1 and GL Clusters 3, 4, and 5, respectively, compared to 321 the pairwise comparisons between ATC groups, **Table S6-A** in **Supporting Information** and **Fig** 322 4. Drugs in GL group 1 showed significantly higher EBGM regarding pulmonary events. Friedman 323 test confirming EBGM profile of selected drugs from GLASSO could be used for comparative 324 analysis of drugs regarding certain indications.











Fig 4. Pairwise Wilcoxon signed-rank test between different classes defined by GLASSO (A)
and pairwise Wilcoxon signed-rank test between different classes defined by GLASSO excluding
Tadalafil (B).

335

336 **DISCUSSION**

337 The future of large-scale biomedical science is data-driven decision-making and AI knowledge-338 based development and validation. AI-enabled technologies can help in better understanding 339 disease indication occurrence and disease determinants or patterns. Quantitative methods have 340 countlessly been applied in various medical fields of study, e.g. measurement of disease frequency, 341 prevalence or incidence; evaluation of source of bias and variation of observational studies; 342 multivariate data analysis of risk factors such as applied logistic regression analysis; machine 343 learning for survival analysis or analysis of time at risk (survival) data; boosting power for clinical 344 trials using AI-assisted analysis, etc. In our study, we aimed to apply AI-driven methodologies 345 involving EBGM and GLASSO techniques in predicting SARS-Cov-2 comorbidity for high-risk 346 populations with hypertension.

348 Quantitative methods, i.e., PPR, RR, ROR, EBGM have been used to detect signals for 349 spontaneously reported data. After filtering data by quantitative methods, we proposed that 350 selected drug-ADE based on drug association mechanism would be a valuable procedure for 351 clinical review and comparison of similar drugs with similar ADE profiles. In this study, we 352 demonstrated a systematic way of filtering and selecting data that addresses the noise inherent to 353 such data. None of these methods are free from including false positive and false negative signals, 354 however, EBGM and the Information Component (IC) are recommended over other quantitative 355 methods when evaluating by mean average precision (16). This helped us to build a model to 356 understand the bias-variance tradeoff to achieve a balance between the two desirable but 357 incompatible features. Given the absence of a gold standard, no available method is 358 overwhelmingly better than the others (18). The confirmatory methods proposed in this study 359 (GLASSO and Friedman test) for assessing quantitative methods could reveal the strengths and 360 drawbacks of the methods.

361

362 Drugs from different branches in the 3D plot represent distinctive effects of pulmonary ADEs on 363 the separation. For example, PC3 is dominated by fungal, PC2 by more pleural and vascular, and 364 PC1 by respiratory tract effects (see Table S1 in Supporting Information). PCs were constructed 365 using the expected counts of a drug and a pulmonary ADE through a linear combination. The 366 spatial separation of drugs indicated that drugs at the perimeter of each branch (numbered) 367 performed disparately regarding pulmonary ADE profiles, suggesting they may not best be 368 managed as having ADE profiles defined by their class. This figure shows the optimal 369 representation of three active variables in biplots acquired by PCA by diminishing the effect of 370 supplementary variables that have no or little influence on the pulmonary ADEs. Using the

Friedman test, we found that these separated drugs have significant differences between their drugclasses and compared to other drug classes.

373

374 The consistency of the Friedman test and GLASSO to capture EBGM signals of drugs used in 375 small and large populations could be a beneficial tool for drug comparative analysis. Xu et al. (20) 376 and Stafford et al. (10) have already applied two methods in pharmacovigilance to animal and 377 human data separately. This study proposed and successfully combined penalized regression 378 together with the non-parametric Friedman test in considering to better visualization of drug-drug 379 and drug-ADE associations. The RR method is widely utilized due to its simplicity and user-380 friendly processing. RR, however, may be highly variable for small occurrences of an event. Our 381 assessment of drugs or ADEs based on RR showed unstable performance, especially for hidden 382 information. The estimates of small occurrences compared to the whole database were also inflated for events. To correct these issues, we introduce 5th percentiles from the lower confidence interval 383 384 of EBGM (EB05) used as a conservative alternative compared to RR.

385

386 EBGM detected that 16 out of 25 pulmonary ADEs in MedDRA databases were associated with 387 macitentan, followed by bosentan with 14 pulmonary ADEs. Both of these drugs belong to the 388 endothelin receptor antagonist class of drugs and are utilized in pulmonary arterial hypertension 389 to prevent vasoconstriction, fibrosis, and inflammation on vascular endothelium and smooth 390 muscle (32). Both drugs are proposed to curb the pulmonary vascular resistance to prevent right 391 heart failure and death, however, pulmonary ADEs of both drugs can be of major concern 392 compared to the outcomes of several other antihypertensives agents we utilized in this study. At 393 the same time, because these two medications are used in a disease affecting pulmonary function

394 and commonly reported ADEs to include therapeutic failure, these drugs were not surprising to 395 emerge among the highest with reported pulmonary ADEs and, in fact, they serve to validate the 396 methods utilized in this paper. Conversely, doxazosin and rilmenidine were found to have the least 397 pulmonary ADEs in selected drugs from hypertension patients since only two ADE signals were 398 detected based on EBGM. Although it can be used in hypertension, doxazosin is primarily utilized 399 for men with benign prostatic hyperplasia and works by blocking alpha-adrenergic receptors in the 400 vascular smooth muscle, resulting in vasodilation (33). Additionally, studies in countries outside 401 of the US suggest that rilmenidine, a sympatholytic, has a favorable ADE profile for patients with 402 hypertension and diabetes, it is not approved in the US (34). After excluding GL Cluster 1, we did 403 see almost the same results for the remaining GL clusters. It is also worth mentioning here that the 404 results are shown in Tables S2, S3, S4, SB-5, and S6-B as well as Figs S1 and S2 in Supporting 405 Information.

406

407 The second group found by EBGM and GL clustering consisted of two drugs from CCBs 408 (nifedipine) and ARBs (candesartan) grouped in combination (Fig 2) and showed four similar 409 pulmonary ADEs: parenchymal lung disorders NEC, pneumothorax and pleural effusions NEC, 410 lower respiratory tract inflammatory and immunologic conditions, and fungal lower respiratory 411 tract infections. Several studies based on these drugs showed effective combination and blood 412 pressure lowering effects in patients with hypertension and appeared an improved side effect 413 profile in comparison with single-agent monotherapy (35-38). This is undoubtedly an interesting 414 finding resulted from our EBGM analysis and demonstrated how these two drugs can be combined 415 and investigated for pharmacokinetic assessment in drug development including bioavailability

416 and bioequivalence, drug safety pharmacovigilance, and efficacy and comparative tolerability of417 the combination of nifedipine and candesartan (39, 40).

418

419 Our previous work showed that quinapril and trandolapril were significantly different from other 420 ACEI and ARB drug classes (11). Separating from its drug class was initially observed in Fig 1 421 when the PCA biplot was performed. However, these two drugs will not be present when more 422 precautionary methods are applied for several reasons: (1) the dataset is no longer the same as 423 before which contain only ACEIs or ARBs. (2) The methods are very different. (3) Several other 424 drugs and ADEs are added to the study, 134 as opposed to only 16 drugs. (4) In our previous work, 425 we only focused on analyzing 13 pulmonary ADEs at the PT level; however, in the current study, 426 we obtained and compare 25 ADEs in HLT groups and each HLT contains several PT ADEs. To 427 be more accurate, ADEs for the 25 ADEs in HLT groups contains approximately 200 different PT 428 vs only 13 ADEs. (5) The whole purpose of this study was to use EBGM as a much more accurate 429 method compared to RR and RR estimation is also better than the PRR method used before. (6) 430 The implementation of the filtering process of penalized regression GLASSO helps eliminate the 431 insignificant and noise-driven reports.

432

Two drugs, tadalafil and sildenafil, are also used for the modulation of dopaminergic pathways and modifying risk factors to prevent and treat erectile dysfunction. Using our database when curating the data for the medicinal products of these drugs and checking their active ingredients of tadalafil and sildenafil, the top products are found to be Adcirca (n=32446) and Revatio (n=21358) marketed for the treatment of pulmonary arterial hypertension, respectively, and Cialis (n=15623) and Viagra (n=20820) marketed to treat erectile dysfunction, respectively. We also assessed

whether these drugs only show up at high doses or not. This also confirmed that the dose has an
insignificant effect on the outcome of ADEs, data are given in Table S7 in Supporting
Information.

442

443 As part of our future work, it is worth mentioning that this study aimed to reveal the potential risk 444 of patients using hypertensive drugs in terms of pulmonary issues. Our database will be updated 445 with MedDRA 24.0 that contains the new COVID-19 terms due to its outbreak. It has encouraged 446 us to involve terms related to viral infections that facilitate the capture of ADEs caused by COVID-447 19 in patients with hypertension in the near future. In addition, the pulmonary ADEs of HLT codes 448 in this study were filtered by setting the highest level, system organ class (SOC), with the focus 449 on respiratory, thoracic, and mediastinal disorders (n=28), and infection class containing viral 450 infection (n=2). We plan to include ADEs from the class of Blood and lymphatic system disorders 451 such as thrombosis, coagulation, or platelet disorders. In the big data era, as the spontaneous 452 reports from different data sources including the FDA FAERS database (21), the Vaccine Adverse 453 Event Reporting System (VAERS) (41, 42), and the WHO International Database are increasing 454 in size; drug profiles based ADEs can be established based on quantitative methods, retrieving the 455 signals, or detecting new signals in large numbers of reports by different methods with the 456 combination of clinical review is need for pharmacovigilance.

457

458 **METHODS**

To derive the desired information from datasets, there are a few main methodological steps in this study. In the following, we briefly illustrate procedures in our workflow integrated by machine

461 learning where some preprocessing points are first presented in **Fig 5**. This figure summarizes the



Fig 5. Workflow of data-driven methodology for pulmonary symptomology in hypertension using machine learning models from preprocessing and dictionary creation to storing tables in the database an analysis.

steps in the preparation and analysis of the ADE database to make a decision and interpret ourresults, each step is detailed in the following subsections:

- 464 1. Working hypothesis: drugs from the same drug class could have different pulmonary ADE
- 465 profiles affecting outcomes in acute respiratory illness, with potential implication in SARS-

466 CoV-2 infection.

- 467 2. Designing error correction techniques for data scrubbing and retrieval.
- 468 3. Implementing data exploration technique for initial data analysis to visually explore and469 understand the characteristics of the data from post-marketing drug safety surveillance.

470 4. Data curation and annotation to organize and integrate data collected from various sources

471 from the FDA, MedDRA, and ATC classification. This phase entails annotation, organization,

472 clustering, and presentation of the assorted data types from the 1DATA databank.

473 5. ADE-associated information retrieval for patients with hypertension provides massive474 collections of reports to investigate adverse drug events based on comparative population data

analysis.

- 476 6. Integration of machine learning models.
- 477 7. Acquiring results after data preprocessing and cleansing that significantly reduces the size of478 data and eliminates insignificant and noise-driven reports.
- 8. and 9. Enhancing decision and interpretation via data-driven machine learning to help identify
 incidences of pulmonary ADEs for potential therapy and confounding factors that may have
 implications for treating patients diagnosed with COVID-19, respectively.

482

483 As a part of data cleaning, we were also challenged by multiple technical issues when combining
484 drugs: (i) there were many drugs' names that did not track a specific standard. (ii) Formulations of

the same active ingredient with different generic or brand names for different routes of administration created confusion in collecting data (for instance, Revatio, Viagra, sildenafil, sildenafil citrate, APO sildenafil, sildenafil film-coated tablet, sildenafil citrate Aurobindo pharma, sildenafil Amneal Pharmaceuticals, Teva sildenafil, sildenafil Pfizer, sildenafil Greenstone, sildenafil Hormosan Filmtabletten, Revathio, sildenafil SUP, etc.). For this purpose, we combined drugs with or without salt, alcohol, etc. from different generic names and brand names.

491

492 **Data Integration**

493 The data were integrated into the 1DATA databank (www.1DATA.life) (20) from multiple 494 sources, including the Food and Drug Administration (FDA) Adverse Drug Events Reporting 495 System (FAERS), the Medical Dictionary for Regulatory Activities (MedDRA), and the ATC 496 classification system. The FAERS database consists of voluntarily or mandatorily reported ADEs 497 from healthcare professionals, manufacturers, and consumers; encompassing drug-related adverse 498 occurrences pertaining to standard use, medical error, overdose, or product quality (21). ADE 499 reports from FAERS are typically coded in accordance with the Preferred Term (PT) level of 500 MedDRA. The MedDRA provides an internationally recognized hierarchical terminology [System 501 Organ Class (SOC), High-Level Group Term (HLGT), High-Level Term (HLT), PT, and Lowest 502 Level Term (LLT)] for coding ADE reports (22). This study aggregates raw ADE reports to terms 503 from the HLT and SOC levels. ATC classification is likewise an internationally applied 504 hierarchical system for active drug substances based on site of action (organ or system) and 505 mechanistic properties (therapeutic, pharmacological, and chemical). Drugs in this study were 506 grouped according to ATC classification. Data integration into 1DATA occurred through the

507 PostgreSQL 13.2 version (PostgreSQL Global Development Group), which allows concatenation
508 of drug and ADE information (20, 23).

509

510 Adverse Drug Event (ADE)

511 ADEs cause approximately 30 billion dollars a year of added health care expenses, along with 512 negative-including fatal-health outcomes (20). The practice of prescribing drugs based on 513 information from drug preapproval labeling may misrepresent or deprecate the incidence and 514 prevalence of specific ADEs. The FDA defines the term 'adverse event' as: "any untoward medical 515 occurrence associated with the use of a drug in humans, whether or not considered drug related, 516 including the following: an adverse event occurring in the course of the use of a drug product in 517 professional practice; an adverse event occurring from drug overdose whether accidental or 518 intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug 519 withdrawal; and any failure of expected pharmacological action" (24, 25).

520

521 Relative Risk (RR)

522 The main method used in this study, Bayesian shrinkage, is based on a baseline frequency, which523 is the relative risk or relative reporting ratio

524
$$\operatorname{RR}_{ij} = \frac{N_{ij}}{E_{ij}}.$$

525 It compares a drug-ADE count, N, to its expected count, *E*. For instance, when N_{ij}/E_{ij} is equal to 526 100, then $drug_i$ and ADE_j occurred 100 times as frequently as the baseline frequency represents. A 527 huge difference of occurrences between two drug-ADE pairs might lead to similar RR due to *E* in

528	the denominator, even statistically the same, but the frequency illustrates sampling variation. When
529	more events of ADE_j are caused by $drug_i$ higher than the same ADE in the database, RR_{ij} >1. Drug-
530	ADE surveillance should be triggered when large RR scores show up for specific drug-ADE pairs.
531	However, the variability of RR for small counts drug-ADE pairs is unreliable, the high value of
532	RR might be accidental.

533

534 Principal Component Analysis (PCA)

Principal component analysis (PCA) was obtained based on the log expected value of RR, log(E), to analyze ADEs for different drugs, to reduce the features from the drug-ADE matrix. The distinct clusters from PCA plots were used to compare the similarities of drugs based on *E*. PCA was conducted using built-in function *PCA* in R (R 3.6.3 version, R Core Team, GNU GPL v2), and PCA biplots were produced using the R package *factoextra*, and 3D PC plots were produced using R package *plotly*.

541

542 Gamma-Poisson Shrinker (GPS)

543 DuMouchel (17) proposed an empirical Bayes approach based on the Gamma-Poisson Shrinker 544 (GPS) algorithm to bring down the inflated value of RR due to small counts without impacting 545 RR associated with large counts. Thus, the drug profile based on ADE could be reconstructed with 546 reduced variation in RR. GPS redefines RR_{ij} as $\lambda_{ij}=\mu_{ij}/E_{ij}$ drawn from a prior distribution with a 547 mixture of two gamma distributions, μ_{ij} is the mean of the Poisson distribution of counts 548 for $drug_i$ and ADE_i

549 prior:
$$\Pi(\lambda | \alpha_1, \beta_1, \alpha_2, \beta_2, P) = P \times \operatorname{gamma}(\lambda | \alpha_1, \beta_1) + (1 - P) \times \operatorname{gamma}(\lambda | \alpha_2, \beta_2)$$

which then gives the posterior probability from the components of the mixture model:

551 posterior:
$$\lambda | N = n \sim \Pi(\lambda | \alpha_1 + n, \beta_1 + E, \alpha_2 + n, \beta_2 + E, Q_n)$$

552 GPS shrinks RR scores by using EBGM from

553
$$EBGM = e^{E(\log \lambda)}$$

The shrinkage abates vagueness by reducing RR scores to a conservative level, which helps to alleviate false-positive signals, avoiding arbitrary drug-ADE assessment. The R package *openEBGM* was used to implement the GPS method (26).

557

558 Correlation Matrix and GLASSO

559 The profile of each drug comprises EBGM of all ADEs. The Pearson correlation matrix was 560 constructed based on the EBGM between pairs of drugs. The vector

 $EB_i = (EB_{i1}, EB_{i2}, \dots, EB_{ip})$

for $i \in \{1, 2, \dots, n\}$ denotes the EBGM corresponding to $drug_i$. The Pearson correlation method determines the associations between pairwise vectors of reported drugs, which are the elements in the correlation matrix. This adjacency matrix was highly dense $(n \times n)$, and it is difficult to graph the network when too many drugs (1131) are present. A penalized regression method, graphical least absolute shrinkage and selection operator (GLASSO), was then introduced to encourage sparsity in the adjacency matrix, in order to plot high dimensional graphs from the correlation matrix (27). An R package called *huge* was utilized to perform GLASSO (28).

570 Drug-ADE Correlation Diagram

571 The MedDRA hierarchy is multi-axial, for example, "influenza" is from the PT level and is 572 encompassed within two SOC levels "Respiratory, thoracic and mediastinal disorders" and "Infections and infestations". Therefore, the columns of EBGM calculations in the drug-ADE 573 574 matrix involve HLTs from the "Respiratory, thoracic and mediastinal disorders" and "Infections 575 and infestations" levels. For better visualization, ADE columns of one drug were put in a block 576 with other rows being zeros. The dimension of a drug-ADE matrix was expanded from $(m \times q)$ to 577 $(m \times mq)$ where $m(\langle n \rangle)$, and m=22 denotes the number of drugs selected by GLASSO from original 578 n=44 drugs, and q=17 denotes selected ADEs described above.

579

580 Reverse Cuthill-Mckee Algorithm

Reverse Cuthill-McKee (RCM) is a bandwidth and profile reduction method, which permutes a sparse matrix into a band matrix with vertices reordered close to the diagonal (29). RCM in this study implemented in MATLAB R2019b (MathWorks Inc., Natick, MA, USA) was applied to arrange the connections between drugs and ADEs to encourage fewer crossings in Circos plots and arc diagrams. Circos plots and arc diagrams were generated using the R packages *edgebundleR*, *igraph, and ggrpah* (30).

587

588 Friedman Test

Using SAS (SAS University Edition version 9.4, North Carolina, U.S), sample differences among
antihypertensive drug groups according to therapeutic main group ATC (ACEIs, ARBs, BBAs,

591 CCBs, and TDs) were evaluated for a pairwise comparison analysis with the assumption that data 592 were not normally distributed using the non-parametric Friedman test for two independent 593 unequal-sized data. The Friedman test was also applied to perform multiple comparison tests (*P*-594 value for statistical significance < 0.05). Pairwise comparison analysis was completed in SAS. The 595 significance level of comparing drug classes against each other was adjusted using a rigorous 596 paired Wilcoxon signed-rank test with Bonferroni correction to control family-wise type I error 597 (31).

598

599 Author contributions

600 Xuan Xu: Data Curation, Investigation, Methodology, Software, Validation, Visualization, 601 Writing - Original Draft Preparation; Jessica Kawakami: Investigation, Conceptualization, 602 Writing - Original Draft Preparation; Nuwan Indika Millagaha Gedara: Data Curation, 603 Investigation, Methodology, Software, Writing – Review & Editing; Jim Riviere: Investigation, 604 Project Administration, Conceptualization, Writing – Review & Editing; **Emma Mever:** 605 Investigation, Conceptualization, Writing – Review & Editing; Gerald J. Wyckoff: Funding Acquisition, Project Administration, Investigation, Conceptualization, Writing - Review & 606 607 Editing; and Majid Jaberi-Douraki: Conceptualization, Data Curation, Formal Analysis, 608 Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, 609 Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing.

611 Data Availability

- 612 The source code and data used to produce results and analyses presented in this manuscript are
- 613 available at
- 614 <u>https://ldata.life/pages/publication/data_driven_methodology_COVID19_related_pharmacovigil</u>
- 615 <u>ance/</u>

616 **References**

- 617 1. Organization WH. Weekly Epidemiological Update—1 December 2020. 2020.
- 618 2. WHO Coronavirus (COVID-19) Dashboard [Available from: <u>https://covid19.who.int/</u>.
- 619 3. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative 620 review. Annals of internal medicine. 2020;173(5):362-7.

621 4. CDC. Coronavirus Disease 2019 (COVID-19): People with Certain Medical Conditions
 622 [Available from: <u>https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-</u>
 623 with-medical-conditions.html.

5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet.
2020;395(10229):1054-62.

6. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al.
2014 evidence-based guideline for the management of high blood pressure in adults: report from
the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama.
2014;311(5):507-20.

631 7. Wiese O, Allwood B, Zemlin A. COVID-19 and the renin-angiotensin system (RAS): A
632 spark that sets the forest alight? Medical Hypotheses. 2020;144:110231.

633 8. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting
634 enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450-4.

635 9. Smith MD, Smith JC. Repurposing Therapeutics for COVID-19: Supercomputer-Based
 636 Docking to theSARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface.

637 10. Stafford EG, Riviere JE, Xu X, Kawakami J, Wyckoff GJ, Jaberi-Douraki M.
638 Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS
639 antagonists with adverse pulmonary safety profiles that have implications for COVID-19
640 morbidity and mortality. Journal of the American Pharmacists Association. 2020.

- 641 11. Stafford EG, Riviere J, Xu X, Gedara NIM, Kawakami J, Wyckoff GJ, et al. Pulmonary
 642 Adverse Event Data in Hypertension with Implications on COVID-19 Morbidity. 2020.
- Rønning M. Coding and classification in drug statistics–From national to global application.
 Norsk epidemiologi. 2001;11(1).
- Tatonetti NP, Patrick PY, Daneshjou R, Altman RB. Data-driven prediction of drug effects
 and interactions. Science translational medicine. 2012;4(125):125ra31-ra31.
- Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
 generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug
 safety. 2001;10(6):483-6.

van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A
comparison of measures of disproportionality for signal detection in spontaneous reporting
systems for adverse drug reactions. Pharmacoepidemiology and drug safety. 2002;11(1):3-10.

- I6. Zorych I, Madigan D, Ryan P, Bate A. Disproportionality methods for pharmacovigilance
 in longitudinal observational databases. Statistical methods in medical research. 2013;22(1):39-56.
- DuMouchel W. Bayesian data mining in large frequency tables, with an application to the
 FDA spontaneous reporting system. The American Statistician. 1999;53(3):177-90.
- Bate A, Evans S. Quantitative signal detection using spontaneous ADR reporting.
 Pharmacoepidemiology and drug safety. 2009;18(6):427-36.
- 19. Duggirala H, Tonning J, Smith E, Bright R, Baker J, Ball R. Data mining at FDA—whitepaper. 2019.
- 20. Xu X, Mazloom R, Goligerdian A, Staley J, Amini M, Wyckoff GJ, et al. Making sense of
 Pharmacovigilance and drug adverse event reporting: comparative similarity association analysis
 using AI machine learning algorithms in dogs and cats. Topics in Companion Animal Medicine.
 2019;37:100366.
- 665 21. FDA Adverse Event Reporting System [Available from: <u>https://open.fda.gov/data/faers/</u>.
- 666 22. Mozzicato P. MedDRA. Pharmaceutical Medicine. 2009;23(2):65-75.
- 667 23. PostgreSQL B. PostgreSQL. Web resource: <u>http://www</u> PostgreSQL org/about. 1996.
- 668 24. FDA. Code of Federal Regulations: 21CFR310.305 2020 [Available from: 669 <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=310.305</u>.
- 670 25. FDA. Code of Federal Regulations: 21CFR314.80 2020 [Available from: 671 <u>https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.80</u>.
- 672 26. Canida T, Ihrie J. openEBGM: An R Implementation of the Gamma-Poisson Shrinker Data
 673 Mining Model. R J. 2017;9(2):499.
- 674 27. Tibshirani R. Regression shrinkage and selection via the lasso. Journal of the Royal
 675 Statistical Society: Series B (Methodological). 1996;58(1):267-88.
- 28. Zhao T, Liu H, Roeder K, Lafferty J, Wasserman L. The huge package for highdimensional undirected graph estimation in R. The Journal of Machine Learning Research.
 2012;13(1):1059-62.
- 679 29. Gibbs NE, Poole J, William G, Stockmeyer PK. An algorithm for reducing the bandwidth 680 and profile of a sparse matrix. SIAM Journal on Numerical Analysis. 1976;13(2):236-50.
- 68130.Bostock MP, Ellis, Russell K, Tarr G. Package 'edgebundleR": Circle Plot with Bundled682EdgesAugust29,2016[Availablefrom: https://cran.r-683project.org/web/packages/edgebundleR/index.html.
- 684 31. Eisinga R, Heskes T, Pelzer B, Te Grotenhuis M. Exact p-values for pairwise comparison
 685 of Friedman rank sums, with application to comparing classifiers. BMC bioinformatics.
 686 2017;18(1):68.
- 687 32. Lexicomp. Specific Lexicomp Online Database [database on the Internet]. Hudson (OH):
 688 Lexicomp Inc. 2016 [Available from: <u>http://online.lexi.com</u>.

689 33. Lepor H, Kaplan SA, Klimberg I, Mobley DF, Fawzy A, Gaffney M, et al. Doxazosin for
690 benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive
691 patients. The Journal of urology. 1997;157(2):525-30.

Meredith PA, Reid JL. Efficacy and Tolerability of Long-Term Rilmenidine Treatment in
Hypertensive Diabetic Patients. American Journal of Cardiovascular Drugs. 2004;4(3):195-200.

Hasebe N, Kikuchi K, Group NCS. Controlled-release nifedipine and candesartan lowdose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine
and Candesartan Combination) Study. Journal of hypertension. 2005;23(2):445-53.

Kjeldsen SE, Sica D, Haller H, Cha G, Gil-Extremera B, Harvey P, et al. Nifedipine plus
candesartan combination increases blood pressure control regardless of race and improves the side
effect profile: DISTINCT randomized trial results. Journal of hypertension. 2014;32(12):2488.

Mancia G, Cha G, Gil-Extremera B, Harvey P, Lewin A, Villa G, et al. Blood pressurelowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup
analysis of the DISTINCT randomised trial. Journal of human hypertension. 2017;31(3):178-88.

703 38. Fujikawa K, Hasebe N, Kikuchi K. Cost-Effectiveness Analysis of Hypertension
704 Treatment: Controlled Release Nifedipine and Candesartan Low-Dose Combination Therapy in
705 Patients with Essential Hypertension—The Nifedipine and Candesartan Combination (NICE706 Combi) Study—. Hypertension research. 2005;28(7):585-91.

707 39. Patterson SD, Jones B. Bioequivalence and statistics in clinical pharmacology: CRC Press;
708 2017.

Midha KK, McKay G. Bioequivalence; its history, practice, and future. The AAPS journal.
2009;11(4):664-70.

41. Chen RT, Rastogi SC, Mullen JR, Hayes SW, Cochi SL, Donlon JA, et al. The vaccine
adverse event reporting system (VAERS). Vaccine. 1994;12(6):542-50.

42. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398-405.